These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 29312943)

  • 1. Therapeutic Application of Pluripotent Stem Cells: Challenges and Risks.
    Martin U
    Front Med (Lausanne); 2017; 4():229. PubMed ID: 29312943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New muscle for old hearts: engineering tissue from pluripotent stem cells.
    Martin U
    Hum Gene Ther; 2015 May; 26(5):305-11. PubMed ID: 25915101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse engineering human neurodegenerative disease using pluripotent stem cell technology.
    Liu Y; Deng W
    Brain Res; 2016 May; 1638(Pt A):30-41. PubMed ID: 26423934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cells and Induced Pluripotent Cancer Cells in Cancer Disease Modeling.
    Zhu D; Kong CSL; Gingold JA; Zhao R; Lee DF
    Adv Exp Med Biol; 2018; 1119():169-183. PubMed ID: 30069853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review of induced pluripotent stem cell technology as a potential clinical therapy for spinal cord injury.
    Kramer AS; Harvey AR; Plant GW; Hodgetts SI
    Cell Transplant; 2013; 22(4):571-617. PubMed ID: 22944020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications.
    Omole AE; Fakoya AOJ
    PeerJ; 2018; 6():e4370. PubMed ID: 29770269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induced pluripotent stem cells in companion animals: how can we move the field forward?
    Barrachina L; Arshaghi TE; O'Brien A; Ivanovska A; Barry F
    Front Vet Sci; 2023; 10():1176772. PubMed ID: 37180067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical applications of pluripotent stem cells and their derivatives: current status and future perspectives.
    Pendse S; Vaidya A; Kale V
    Regen Med; 2022 Sep; 17(9):677-690. PubMed ID: 35703035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and functional resemblance of differentiated cells derived from isogenic human iPSCs and SCNT-derived ESCs.
    Zhao MT; Chen H; Liu Q; Shao NY; Sayed N; Wo HT; Zhang JZ; Ong SG; Liu C; Kim Y; Yang H; Chour T; Ma H; Gutierrez NM; Karakikes I; Mitalipov S; Snyder MP; Wu JC
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11111-E11120. PubMed ID: 29203658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem cell therapy of myocardial infarction: a promising opportunity in bioengineering.
    Jiang B; Yan L; Shamul JG; Hakun M; He X
    Adv Ther (Weinh); 2020 Mar; 3(3):. PubMed ID: 33665356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current progress and potential practical application for human pluripotent stem cells.
    Philonenko ES; Shutova MV; Chestkov IV; Lagarkova MA; Kiselev SL
    Int Rev Cell Mol Biol; 2011; 292():153-96. PubMed ID: 22078961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome-wide mapping of miRNAs expressed in embryonic stem cells and pluripotent stem cells generated by different reprogramming strategies.
    Zhao B; Yang D; Jiang J; Li J; Fan C; Huang M; Fan Y; Jin Y; Jin Y
    BMC Genomics; 2014 Jun; 15(1):488. PubMed ID: 24942538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming.
    Abdal Dayem A; Lee SB; Kim K; Lim KM; Jeon TI; Seok J; Cho AS
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming mechanisms influence the maturation of hematopoietic progenitors from human pluripotent stem cells.
    Heo HR; Song H; Kim HR; Lee JE; Chung YG; Kim WJ; Yang SR; Kim KS; Chun T; Lee DR; Hong SH
    Cell Death Dis; 2018 Oct; 9(11):1090. PubMed ID: 30356076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How far are induced pluripotent stem cells from the clinic?
    Li M; Chen M; Han W; Fu X
    Ageing Res Rev; 2010 Jul; 9(3):257-64. PubMed ID: 20362696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human induced pluripotent stem cells--from mechanisms to clinical applications.
    Drews K; Jozefczuk J; Prigione A; Adjaye J
    J Mol Med (Berl); 2012 Jul; 90(7):735-45. PubMed ID: 22643868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondrial and metabolic remodeling during reprogramming and differentiation of the reprogrammed cells.
    Choi HW; Kim JH; Chung MK; Hong YJ; Jang HS; Seo BJ; Jung TH; Kim JS; Chung HM; Byun SJ; Han SG; Seo HG; Do JT
    Stem Cells Dev; 2015 Jun; 24(11):1366-73. PubMed ID: 25590788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expansion and long-term maintenance of induced pluripotent stem cells in stirred suspension bioreactors.
    Shafa M; Sjonnesen K; Yamashita A; Liu S; Michalak M; Kallos MS; Rancourt DE
    J Tissue Eng Regen Med; 2012 Jun; 6(6):462-72. PubMed ID: 21761573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcriptomic analysis of pluripotent stem cells: insights into health and disease.
    Yeo JC; Ng HH
    Genome Med; 2011 Oct; 3(10):68. PubMed ID: 22035782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing what's lost: a new era of stem cell therapy for Parkinson's disease.
    Fan Y; Winanto ; Ng SY
    Transl Neurodegener; 2020; 9():2. PubMed ID: 31911835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.